肝细胞癌外科治疗进展

doi:10.16139/j.1007-9610.2022.02.005

摘要/Abstract

中图分类号:

R735.7

黄纪伟, 邱国腾, 曾勇. 肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 113-118.

HUANG Jiwei, QIU Guoteng, ZENG Yong. Advances in surgical treatment of hepatocellular carcinoma[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 113-118.

参考文献 53

[1]	Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends[J]. J Hepatol, 2020, 72(2):250-261. doi: S0168-8278(19)30519-7 pmid: 31954490
[2]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. doi: 10.3322/caac.21492 URL
[3]	Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality[J]. Hepatology, 2015, 61(1):191-199. doi: 10.1002/hep.27388 URL
[4]	Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma[J]. J He-patol, 2020, 72(2):262-276.
[5]	Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):6. doi: 10.1038/s41572-020-00240-3 pmid: 33479224
[6]	Labgaa I, Tabrizian P, Titano J, et al. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma[J]. HPB (Oxford), 2019, 21(11):1497-1504. doi: 10.1016/j.hpb.2019.03.360 URL
[7]	Gao Q, Anwar IJ, Abraham N, et al. Liver transplantation for hepatocellular carcinoma after downstaging or brid-ging therapy with immune checkpoint inhibitors[J]. Can-cers (Basel), 13(24):6307.
[8]	Prodeau M, Drumez E, Duhamel A, et al. An ordinal model to predict the risk of symptomatic liver failure in patients with cirrhosis undergoing hepatectomy[J]. J He-patol, 2019, 71(5):920-929.
[9]	Vauthey JN, Abdalla EK, Doherty DA, et al. Body surface area and body weight predict total liver volume in Western adults[J]. Liver Transpl, 2002, 8(3):233-240. doi: 10.1053/jlts.2002.31654 URL
[10]	Kawaguchi Y, Lillemoe HA, Vauthey JN. Surgical resection: old dog, any new tricks?[J]. Clin Liver Dis, 2020, 24(4):637-655. doi: 10.1016/j.cld.2020.07.004 URL
[11]	Ogata S, Belghiti J, Farges O, et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma[J]. Br J Surg, 2006, 93(9):1091-1098. doi: 10.1002/bjs.5341 URL
[12]	Sandström P, Røsok BI, Sparrelid E, et al. ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: results from a Scandinavian multicenter randomized controlled trial(LIGRO Trial)[J]. Ann Surg, 2018, 267(5):833-840. doi: 10.1097/SLA.0000000000002511 pmid: 28902669
[13]	洪德飞, 彭淑牖, 刘允怡. ALPPS治疗肝细胞癌10年回望:永恒的理念慎选的术式[J]. 中华外科杂志, 2022, 60(2):113-116.
[14]	国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2):288-303.
[15]	Troisi RI, Berardi G, Morise Z, et al. Laparoscopic and open liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis: multicentre propensity score-matched study[J]. Br J Surg, 2021, 108(2):196-204. doi: 10.1093/bjs/znaa041 pmid: 33711132
[16]	Berardi G, Morise Z, Sposito C, et al. Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis[J]. J Hepatol, 2020, 72(1):75-84. doi: 10.1016/j.jhep.2019.08.032 URL
[17]	Harimoto N, Yoshizumi T, Fujimoto Y, et al. Surgery for hepatocellular carcinoma in patients with Child-Pugh B cirrhosis: hepatic resection versus living donor liver transplantation[J]. World J Surg, 2018, 42(8):2606-2616. doi: 10.1007/s00268-018-4493-1 URL
[18]	Kawaguchi Y, Hasegawa K, Tzeng CD, et al. Performance of a modified three-level classification in stratifying open liver resection procedures in terms of complexity and postoperative morbidity[J]. Br J Surg, 2020, 107(3):258-267. doi: 10.1002/bjs.11351 pmid: 31603540
[19]	Reich H, McGlynn F, DeCaprio J, et al. Laparoscopic excision of benign liver lesions[J]. Obstet Gynecol, 1991, 78(5 Pt 2):956-568. pmid: 1833688
[20]	周伟平, 孙志宏, 吴孟超, 等. 经腹腔镜肝叶切除首例报道[J]. 肝胆外科杂志, 1994, 2(2):82.
[21]	Yoon YI, Kim KH, Kang SH, et al. Pure laparoscopic versus open right hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a propensity score matched analysis[J]. Ann Surg, 2017, 265(5):856-863. doi: 10.1097/SLA.0000000000002072 URL
[22]	Schmelzle M, Krenzien F, Schöning W, et al. Laparosco-pic liver resection: indications, limitations, and economic aspects[J]. Langenbecks Arch Surg, 2020, 405(6):725-735. doi: 10.1007/s00423-020-01918-8 URL
[23]	Xiangfei M, Yinzhe X, Yingwei P, et al. Open versus laparoscopic hepatic resection for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Surg Endosc, 2019, 33(8):2396-2418. doi: 10.1007/s00464-019-06781-3 pmid: 31139980
[24]	Cucchetti A, Qiao GL, Cescon M, et al. Anatomic versus nonanatomic resection in cirrhotic patients with early hepatocellular carcinoma[J]. Surgery, 2014, 155(3):512-521. doi: 10.1016/j.surg.2013.10.009 URL
[25]	Jiao S, Li G, Zhang D, et al. Anatomic versus nona-natomic resection for hepatocellular carcinoma, do we have an answer? a meta-analysis[J]. Int J Surg, 2020, 80:243-255. doi: 10.1016/j.ijsu.2020.05.008 URL
[26]	Kobayashi Y, Kawaguchi Y, Kobayashi K, et al. Portal vein territory identification using indocyanine green fluorescence imaging: technical details and short-term outcomes[J]. J Surg Oncol, 2017, 116(7):921-931. doi: 10.1002/jso.24752 pmid: 28695566
[27]	Satou S, Ishizawa T, Masuda K, et al. Indocyanine green fluorescent imaging for detecting extrahepatic metastasis of hepatocellular carcinoma[J]. J Gastroenterol, 2013, 48(10):1136-1143. doi: 10.1007/s00535-012-0709-6 URL
[28]	He P, Huang T, Fang C, et al. Identification of extrahepatic metastasis of hepatocellular carcinoma using indocyanine green fluorescence imaging[J]. Photodiagnosis Photodyn Ther, 2019, 25:417-420. doi: 10.1016/j.pdpdt.2019.01.031 URL
[29]	Li WF, Al-Taher M, Yu CY, et al. Super-selective intra-arterial indocyanine green administration for near-infrared fluorescence-based positive staining of hepatic segmentation: a feasibility study[J]. Surg Innov, 2021, 28(6):669-678. doi: 10.1177/1553350621996972 URL
[30]	Ueno M, Hayami S, Sonomura T, et al. Indocyanine green fluorescence imaging techniques and interventional radiology during laparoscopic anatomical liver resection (with video)[J]. Surg Endosc, 2018, 32(2):1051-1055. doi: 10.1007/s00464-017-5997-8 URL
[31]	Di Benedetto F, Petrowsky H, Magistri P, et al. Robotic liver resection: hurdles and beyond[J]. Int J Surg, 2020, 82S:155-162. doi: 10.1016/j.ijsu.2020.05.070 pmid: 32504813
[32]	Hu M, Liu Y, Li C, et al. Robotic versus laparoscopic liver resection in complex cases of left lateral sectionectomy[J]. Int J Surg, 2019, 67:54-60. doi: 10.1016/j.ijsu.2019.05.008 URL
[33]	Villanueva A. Hepatocellular Carcinoma[J]. N Engl J Med, 2019, 380(15):1450-1462. doi: 10.1056/NEJMra1713263 URL
[34]	Zheng K, Zhu X, Fu S, et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial[J]. Radiology, 2022, 303(2):455-464. doi: 10.1148/radiol.211545 URL
[35]	Ding X, Sun W, Li W, et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a prospective randomized study[J]. Cancer, 2021, 127(20):3782-3793. doi: 10.1002/cncr.33677 URL
[36]	Hamaoka M, Kobayashi T, Kuroda S, et al. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: a retrospective cohort study[J]. Int J Surg, 2017, 44:223-228. doi: 10.1016/j.ijsu.2017.06.082 URL
[37]	Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma—a strategy to increase resectability[J]. Ann Surg Oncol, 2007, 14(12):3301-3309. doi: 10.1245/s10434-007-9549-7 URL
[38]	Kokudo T, Hasegawa K, Matsuyama Y, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion[J]. J Hepatol, 2016, 65(5):938-943. doi: 10.1016/j.jhep.2016.05.044 URL
[39]	Zhang XP, Gao YZ, Chen ZH, et al. An eastern hepatobiliary surgery hospital/portal vein tumor thrombus sco-ring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study[J]. Hepatology, 2019, 69(5):2076-2090. doi: 10.1002/hep.30490 URL
[40]	Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019, 37(24):2141-2151. doi: 10.1200/JCO.18.02184 URL
[41]	Liou H, Mody K, Boyle AW, et al. Neoadjuvant radiation lobectomy and immunotherapy for angioinvasive HCC resulting in complete pathologic response[J]. Hepatology, 2021, 74(1):525-527. doi: 10.1002/hep.31675 URL
[42]	Liu S, Guo L, Li H, et al. Postoperative adjuvant trans-arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Ann Surg Oncol, 2018, 25(7):2098-2104. doi: 10.1245/s10434-018-6438-1 URL
[43]	Liang L, Li C, Diao YK, et al. Survival benefits from adjuvant transcatheter arterial chemoembolization in patients undergoing liver resection for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Therap Adv Gastroenterol, 2020, 13:1756284820977693.
[44]	Sun J, Yang L, Shi J, et al. Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: an open-label randomized controlled trial[J]. Radiother Oncol, 2019, 140:20-25. doi: 10.1016/j.radonc.2019.05.006 URL
[45]	Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11):693-699. doi: 10.1056/NEJM199603143341104 URL
[46]	Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival[J]. Hepatology, 2001, 33(6):1394-1403. pmid: 11391528
[47]	Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan Criteria: a retrospective, exploratory analysis[J]. Lancet Oncol, 2009, 10(1):35-43. doi: 10.1016/S1470-2045(08)70284-5 pmid: 19058754
[48]	Kwong A, Mehta N. Expanding the limits of liver transplantation for hepatocellular carcinoma: is there a limit?[J]. Clin Liver Dis, 2021, 25(1):19-33. doi: 10.1016/j.cld.2020.08.002 URL
[49]	Hameed B, Mehta N, Sapisochin G, et al. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carci-noma meeting the Milan Criteria[J]. Liver Transpl, 2014, 20(8):945-951. doi: 10.1002/lt.23904 URL
[50]	Mehta N, Dodge JL, Grab JD, et al. National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and wait time[J]. Hepatology, 2020, 71(3):943-954. doi: 10.1002/hep.30879 pmid: 31344273
[51]	Fernandez-Sevilla E, Allard MA, Selten J, et al. Recurrence of hepatocellular carcinoma after liver transplantation: is there a place for resection?[J]. Liver Transpl, 2017, 23(4):440-447. doi: 10.1002/lt.24742 URL
[52]	de′Angelis N, Landi F, Carra MC, et al. Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review[J]. World J Gastroenterol, 2015, 21(39):11185-11198.
[53]	Halazun KJ, Najjar M, Abdelmessih RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story[J]. Ann Surg, 2017, 265(3):557-564. doi: 10.1097/SLA.0000000000001966 pmid: 27611615

肝细胞癌外科治疗进展

Advances in surgical treatment of hepatocellular carcinoma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 53

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱正纲. 胃癌外科综合治疗的若干进展与展望[J]. 外科理论与实践, 2023, 28(01): 1-6.
[2]	任新平, 李军建, 张杰, 詹维伟. 超声造影在肝局灶性病变诊疗中的应用进展[J]. 诊断学理论与实践, 2022, 21(06): 684-690.
[3]	陈益定, 吴世杰. 遗传性乳腺癌外科治疗[J]. 外科理论与实践, 2022, 27(05): 392-395.
[4]	张吉祥, 谢智华, 综述, 李炜, 姜小清, 审校. 肝内胆管癌的分型和外科治疗热点[J]. 外科理论与实践, 2022, 27(05): 478-482.
[5]	杨雪, 刘锦, 王铮, 陶杰, 郝杰, 李宇, 孙昊. 他克莫司降低肝移植病人ERCP术后胰腺炎发生的临床观察[J]. 外科理论与实践, 2022, 27(03): 253-255.
[6]	陈承坤综述, 郭伯敏, 邓先兆, 伍波, 樊友本审校. 甲状腺髓样癌的诊治现状[J]. 外科理论与实践, 2022, 27(03): 276-280.
[7]	包全, 邢宝才. 复杂双叶多发性结肠直肠癌肝转移外科治疗策略[J]. 外科理论与实践, 2022, 27(02): 128-130.
[8]	马婧嶔, 杨敏捷, 颜志平. 精细TACE的治疗目标与栓塞终点[J]. 外科理论与实践, 2022, 27(02): 131-133.
[9]	孙惠川. 肝细胞癌转化治疗的现状与展望[J]. 外科理论与实践, 2022, 27(02): 134-138.
[10]	吴浩翔, 吕子成, 侯宇宸, 张子杰, 乔子耘, 冯浩, 夏强. 儿童肝移植中他克莫司浓度个体内变异[J]. 外科理论与实践, 2022, 27(02): 145-151.
[11]	张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜. 肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157.
[12]	张磊, 毛家玺, 李涛, 滕飞, 孙克彦. 术前免疫炎症反应对原发性胆汁性胆管炎肝移植病人预后影响的双中心回顾性研究[J]. 外科理论与实践, 2022, 27(02): 158-164.
[13]	管涛(综述), 张倜, 王鲁(审校). 肝细胞癌肺转移的潜在机制和治疗进展[J]. 外科理论与实践, 2022, 27(02): 180-184.
[14]	朱鹏, 廖威, 张必翔, 陈孝平. 机器人肝癌肝切除应用现状与前景[J]. 外科理论与实践, 2022, 27(02): 95-99.
[15]	冯浩, 吕子成, 夏强. 肝癌肝移植全过程管理及治疗进展[J]. 外科理论与实践, 2022, 27(02): 119-122.